IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.96
-0.62 (-6.47%)
As of 1:11PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close9.58
Open9.51
Bid9.04 x 1200
Ask9.05 x 900
Day's Range8.94 - 9.60
52 Week Range7.85 - 19.90
Volume503,593
Avg. Volume1,657,034
Market Cap1.104B
Beta (3Y Monthly)3.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire6 days ago

    Iovance Biotherapeutics to Participate at November Investor Conferences

    SAN CARLOS, Calif., Nov. 13, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating.

  • GlobeNewswire13 days ago

    Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its third quarter 2018 financial results and provided a corporate update. Following our recent end of Phase 2 meeting with the FDA, we released information about the meeting outcome and our US registration path, receipt of RMAT designation for metastatic melanoma, an abbreviated set of our latest clinical data, and conducted a successful round of financing. The company is now in a very strong financial position which will allow us to pursue our registration program to commercialize our TIL therapy,” said Dr. Maria Fardis, Ph.D., MBA, president and chief executive officer of Iovance Biotherapeutics.

  • GlobeNewswire13 days ago

    Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that a presentation of new data from the ongoing Phase 2 lifileucel metastatic melanoma trial (C-144-01) will occur at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. from November 7-11, 2018. Dr. Amod Sarnaik, from H. Lee Moffitt Cancer Center, the lead investigator in the C-144-01 study, will discuss the new data as an oral presentation on Sunday, November 11, 2018.  These results will also be presented as a poster beginning November 9, 2018.  The company will also host a live webcast of its melanoma program at an event for analysts and investors on Friday, November 9, 2018 from 6:30 – 8:30pm ET during the SITC meeting.

  • GlobeNewswire20 days ago

    Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018

    SAN CARLOS, Calif., Oct. 30, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating.

  • GlobeNewswire21 days ago

    Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will host a live webcast of its Melanoma Program Update event for Analysts and Investors on Friday, November 9, 2018 from 6:30 – 8:30pm ET during the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. Iovance’s leadership team will present an overview of the company’s immuno-oncology pipeline and the latest clinical data as well as the planned registration pathway for lifileucel, which was recently discussed with the U.S. Food and Drug Administration (FDA) and has received RMAT designation, the manufacturing progress leading to a commercial process and commercialization plans for lifileucel.

  • GlobeNewswirelast month

    Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A., a subsidiary of Orgenesis Inc. (ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO), today announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.

  • GlobeNewswirelast month

    Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering

    Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the closing of an underwritten public offering of 25,300,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are approximately $252.2 million.  The shares of common stock issued and sold in the offering include 3,300,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less the underwriting discounts and commissions.

  • GlobeNewswirelast month

    Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $220 Million of Common Stock

    Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at a public offering price of $9.97 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be $219.3 million.  In addition, Iovance has granted the underwriters a 30-day option to purchase up to 3,300,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions.

  • GlobeNewswirelast month

    Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock

    Iovance Biotherapeutics, Inc. (IOVA) (“Iovance” or “Company”), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Iovance intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, less the underwriting discounts and commissions.

  • GlobeNewswirelast month

    Iovance Biotherapeutics Reports Results from FDA End of Phase 2 meeting and Provides Updates About the Company’s Clinical Program

    —FDA acknowledged acceptability of a single-arm cohort for registration in metastatic melanoma post PD-1 blocking antibody and, if BRAF mutation positive, a BRAF inhibitor or.

  • GlobeNewswire2 months ago

    Iovance Biotherapeutics to Present at the 2018 Cantor Global Healthcare Conference

    SAN CARLOS, Calif., Sept. 26, 2018-- Iovance Biotherapeutics, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced that ...

  • ACCESSWIRE2 months ago

    Immuno Oncology & Targeted Therapy Companies Set to Breakout

    HENDERSON, NV / ACCESSWIRE / September 12, 2018 / Immuno Oncology has been getting investors revved up in 2018. Abpro and Neon announced IPOs and recently, German biotech Affimed agreed to an alliance with Roche's Genentech to discover new cancer immunotherapies with an amazing $5 billion dollar deal. Roche is not the only major player in Immuno Oncology, and you can bet their competition is working to make their own splash announcements in the coming months.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and Iovance Biotherapeutics

    NEW YORK, NY / ACCESSWIRE / September 7, 2018 / Arrowhead Pharmaceuticals exploded on positive data results on Thursday while shares of Iovance Biotherapeutics were deep in the red on its own concerning ...

  • ACCESSWIRE3 months ago

    Iovance Biotherapeutics Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Iovance Biotherapeutics Inc (NASDAQ: IOVA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...

  • ACCESSWIRE4 months ago

    Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).

  • ACCESSWIRE5 months ago

    A Savvy Biotech Investor Is Betting Up To $25 Million Dollars On This $8 Stock Returning 250%... Or More?

    Top-notch Great Point Partners is investing up to $25 million in Orgenesis' (ORGS) manufacturing subsidiary to enable global expansion. Company is already generating growing revenue, and this specialist healthcare fund investment substantiates the ORGS growth opportunity. Demand for CDMOs, like ORGS, is growing as more cell therapies (like gene therapies and CAR-T cells) come to market in the coming years.

  • ACCESSWIRE5 months ago

    Iovance Biotherapeutics and Three Additional Biotech Stocks on Our Research Desk's Radar

    Stock Research Monitor: JAGX, JAZZ, and LJPC LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration . On Thursday, June 14, ...

  • ACCESSWIRE6 months ago

    Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a research collaboration deal with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance") to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs), for use in the treatment of cancer.

  • ACCESSWIRE6 months ago

    Free Breakfast Technical Briefing on Intrexon and Three Other Biotech Stocks

    Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.